Cargando…
EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report
Primary malignant fibrous histiocytoma of the lung (PMFHL) is extremely rare. It is more common in the right lung and has no specific symptoms. Lymph node metastasis is rare, but hematogenous metastasis is more common. The common metastatic sites are the brain and bone. In this study, a 59-year-old...
Autores principales: | Zhang, Shuai, Liao, Xuqiang, Chen, Jiawei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484492/ https://www.ncbi.nlm.nih.gov/pubmed/36132152 http://dx.doi.org/10.3389/fonc.2022.978327 |
Ejemplares similares
-
Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
por: Shi, Liang, et al.
Publicado: (2023) -
Pleomorphic malignant fibrous histiocytoma in bladder diverticulum
por: García Alvarez, C., et al.
Publicado: (2019) -
Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022) -
Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018) -
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)